High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who…

By S. Branford, Z. Rudzki, Sonya Walsh, A. Grigg, C. Arthur, K. Taylor, R. Herrmann, K. Lynch, T. Hughes. Blood, 2002

707 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/4034d2fd64e1d169b60746e0a618c5e08da330db

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. Brian J. Druker

In Rheumatology

1. Brian J. Druker

Citations in the corpus

• A small molecule–kinase interaction map for clinical kinase inhibitors (2005, background): “One of the most commonly observed mutant forms in patients, T315I, is almost completely resistant to imatini”
• Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. (2003, background): “4 Met351Thr 5 CP AP Imatinib withdrawn (7) because of MBC,”